INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as…
BioMech recognized for its digital advancements in healthcare, allowing patients and clinicians to quantitatively measure and monitor pre-and post-treatment function…
Synfini Unites Neuro-Symbolic AI, Robotic Automation, and World-class Chemistry Data to Dramatically Accelerate Drug Discovery; Company Leverages More Than $40 Million in Non-dilutive SRI Development and $1M in Private Investment, Including…
Unified front door streamlines healthcare experience for users, facilitates aggregated reporting for carriers and employers – ensuring transparency and performance…
CARMEL, Ind., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment…
LINCOLN, Neb., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NRC Health is pleased to announce that Lurie Children’s Hospital of Chicago…
– Phase 1 data for CT-388, a once-weekly injectable, dual GLP-1/GIP receptor agonist in development for the treatment of obesity…
NEW YORK, NY, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Vice Health and Wellness Inc. (Vice) (CSE: VICE) (OTC Pink: VICFF)…